US2017210795A1PendingUtilityA1

Uses and compositions for treatment of psoriatic arthritis

Assignee: ABBVIE BIOTECHNOLOGY LTDPriority: Apr 10, 2006Filed: Apr 13, 2017Published: Jul 27, 2017

Est. expiryApr 10, 2026(expired)· nominal 20-yr term from priority

Inventors:John R. Medich Robert L. Wong Renee J. Perdok Eric Sasso Rebecca S. Hoffman Philip Mease Christopher T. Ritchlin

A61P 37/00A61P 19/02C07K 2317/76C07K 2317/21A61K 2039/505A61K 2039/55G01N 2800/102A61K 2039/545C07K 16/241C07K 2317/565

PatentIndex Score

Cited by

References

Claims

Abstract

The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of psoriatic arthritis in a subject.

Claims

exact text as granted — not AI-modified

What is claimed: 
     
         1 . A method of treating PsA in a subject having a subtherapeutic response to treatment with a TNFα inhibitor comprising administering the TNFα inhibitor to the subject on a weekly dosing regimen, such that PsA is treated.

Join the waitlist — get patent alerts

Track US2017210795A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.